Tonix Pharmaceuticals Holding Corp. (TNXP) SEC Filing 8-K Material Event for the period ending Monday, March 11, 2019

Tonix Pharmaceuticals Holding Corp.

CIK: 1430306 Ticker: TNXP

View differences made from one to another to evaluate Tonix Pharmaceuticals Holding Corp.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Tonix Pharmaceuticals Holding Corp..


Assess how Tonix Pharmaceuticals Holding Corp.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Tonix Pharmaceuticals Holding Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Tonix Pharmaceuticals Holding Corp. provided additional information to their SEC Filing as exhibits

Ticker: TNXP
CIK: 1430306
Form Type: 8-K Corporate News
Accession Number: 0001387131-19-001811
Submitted to the SEC: Mon Mar 11 2019 7:05:23 AM EST
Accepted by the SEC: Mon Mar 11 2019
Period: Monday, March 11, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: